enGene (NASDAQ:ENGN) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of enGene (NASDAQ:ENGN) from an outperform rating to a strong-buy rating in a report issued on Tuesday, MarketBeat.com reports. The brokerage currently has $27.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. Morgan Stanley lowered their price target on enGene from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Friday, September 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research note on Tuesday, October 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of enGene in a research note on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, enGene presently has an average rating of “Moderate Buy” and an average price target of $22.38.

enGene Stock Down 2.9%

ENGN opened at $8.43 on Tuesday. The company has a fifty day moving average of $7.27 and a two-hundred day moving average of $4.97. The stock has a market capitalization of $431.53 million, a price-to-earnings ratio of -4.44 and a beta of -0.27. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $11.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.34 and a current ratio of 10.34.

enGene (NASDAQ:ENGN) last posted its earnings results on Thursday, September 11th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, research analysts expect that enGene will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

Hedge funds have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. lifted its stake in enGene by 2.7% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after purchasing an additional 41,874 shares in the last quarter. MAI Capital Management increased its holdings in shares of enGene by 11.0% in the first quarter. MAI Capital Management now owns 78,067 shares of the company’s stock valued at $350,000 after purchasing an additional 7,756 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in enGene during the second quarter worth approximately $280,000. ADAR1 Capital Management LLC purchased a new position in enGene during the first quarter worth approximately $107,000. Finally, Paloma Partners Management Co acquired a new position in enGene during the second quarter worth $38,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.